Emgality OverviewGalcanezumab, marketed under the trade name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is directed against calcitonin-related polypeptides alpha and beta. This drug was developed by Eli Lilly & Co. As of July2017[update]. The drug was approved by the US FDA in September 2018, becoming the third marketed CGRP inhibitor for the United States. See also Oth...
Read more Emgality Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Galcanezumab
Recent Emgality Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 120mg/ml
NDC Database Records for Emgality: (2 results)Sorted by National Drug Code
- 0002-1436 Emgality 120 mg/ml Subcutaneous Injection, Solution by Eli Lilly and Company
- 0002-2377 Emgality 120 mg/ml Subcutaneous Injection, Solution by Eli Lilly and Company